Case study: neuroleptic withdrawal dyskinesia exacerbated by ongoing stimulant treatment.
Risk factors for neuroleptic withdrawal dyskinesia in children have not been well studied. The authors present a case of a child who had been treated with a combination of neuroleptics and stimulants for nonpsychotic aggressive behavior. A severe withdrawal dyskinesia precipitated by neuroleptic tapering was ameliorated by discontinuation of the psycho-stimulant. Although stimulants have been reported to increase certain involuntary movement disorders, this is the first known report of psychostimulant exacerbation of withdrawal dyskinesia.
Department of Psychiatry, University of Massachusetts Medical Center, Worcester 01655, USA.
D F
DF
Connor
S
S
Benjamin
K R
KR
Ozbayrak
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003913:Dextroamphetamine / Q000008:administration & dosage / Q000627:therapeutic use*; D004155:Diphenhydramine / Q000008:administration & dosage / Q000627:therapeutic use*; D005473:Fluoxetine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy*; D009069:Movement Disorders / Q000209:etiology*; D010546:Perphenazine / Q000008:administration & dosage / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D013375:Substance Withdrawal Syndrome / Q000150:complications*; D014743:Videotape Recording
D014150:Antipsychotic Agents; D005473:Fluoxetine; D004155:Diphenhydramine; D010546:Perphenazine; D003913:Dextroamphetamine